



Outcome of allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission: a single institution study

Eun-Jung Lee, MD, Ji Yoon Han, MD, Jae Wook Lee, MD, Pil-Sang Jang, MD, PhD, Nack-Gyun Chung, MD, PhD, Dae-Chul Jeong, MD, PhD, Bin Cho, MD, PhD, Hack-Ki Kim, MD, PhD

Department of Pediatrics, The Catholic University of Korea, School of Medicine, Seoul, Korea

Purpose: The survival rate for childhood acute lymphoblastic leukemia (ALL) has improved significantly. However, overall prognosis for the 20 to 25% of patients who relapse is poor, and allogeneic hematopoietic stem cell transplantation (HSCT) offers the best chance for cure. In this study, we identified significant prognostic variables by analyzing the outcomes of allogeneic HSCT in ALL patients in second complete remission (CR).

Methods: Fifty-three ALL patients (42 men, 79%) who received HSCT in second CR from August 1991 to February 2009 were included (26 sibling donor HSCTs, 49%; 42 bone marrow transplantations, 79%). Study endpoints included cumulative incidence of acute and chronic graft-versus-host disease (GVHD), relapse, 1-year transplant-related mortality (TRM), disease-free survival (DFS), and overall survival (OS).

Results: Cumulative incidences of acute GVHD (grade 2 or above) and chronic GVHD were 45.3% and 28.5%, respectively. The estimated 5-year DFS and OS for the cohort was 45.2±6.8% and 48.3±7%, respectively. Only donor type, i.e., sibling versus unrelated, showed significant correlation with DFS in multivariate analysis ($P=0.010$). The rates of relapse and 1 year TRM were 28.9±6.4% and 26.4±6.1%, respectively, and unrelated donor HSCT ($P=0.002$) and HLA mismatch ($P=0.022$) were significantly correlated with increased TRM in univariate analysis.

Conclusion: In this single institution study spanning more than 17 years, sibling donor HSCT was the only factor predicting a favorable result in multivariate analysis, possibly due to increased TRM resulting from unrelated donor HSCT.

Key words: Acute lymphoblastic leukemia, Child, Second complete remission, Transplantation

Received: 15 September 2011, Revised: 31 October 2011

Accepted: 14 November 2011

Corresponding author: Bin Cho, MD, PhD

Department of Pediatrics, Seoul St. Mary's Hospital, The Catholic University of Korea School of Medicine, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea

Tel: +82-2-2258-6187, Fax: +82-2-588-3589

E-mail: chobinkr@catholic.ac.kr

Copyright © 2012 by The Korean Pediatric Society

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Despite major improvements in the overall survival of children with acute lymphoblastic leukemia (ALL), for the 20 to 25% of patients who relapse, the prognosis remains poor¹⁾. Notwithstanding its potential complications, allogeneic hematopoietic stem cell transplantation (HSCT), preferably from a matched sibling donor (MSD), is known to result in better outcome rather than chemotherapy only in second complete remission (CR)²⁻⁴⁾. With improvements in human leukocyte antigen (HLA) typing and supportive care of transplant-related complications, recent evidence suggests similar outcomes when comparing the results of MSD HSCT and matched unrelated (MUD) HSCT⁵⁻⁷⁾. However, most of the patients undergoing transplantation will fail to be cured of their disease, emphasizing the need to identify important prognostic factors in children who receive HSCT, as well as novel therapeutic modalities.

Previous analyses indicate that the duration of first remission has overall prognostic significance for children with ALL who receive allogeneic HSCT after first relapse^{6,7)}. Other important factors include the conditioning regimen utilized as well as the disease status at the time of transplantation^{8,9)}. Efforts to identify other significant prognostic variables are key to maximizing the efficacy of allogeneic HSCT in childhood ALL, and improve upon its current shortcomings.

In this study, we retrospectively reviewed the results of allogeneic HSCT undertaken in children with ALL in second CR, during a period spanning more than 17 years at a single institution, with the aim of summarizing overall therapeutic outcome for these children, identifying major prognostic variables, and comparing our institution results for MSD HSCT and MUD HSCT.

Materials and methods

1. Patient cohort

1) Pre-transplantation

Patients diagnosed with ALL, who received allogeneic HSCT in second CR from August, 1991 to February, 2009 at the Department of Pediatrics, The Catholic University of Korea, were included. Recipients of cord blood transplantation or familial donor transplantation with 1 antigen or more mismatches were excluded from the study group. Overall, 53 patients (42 male, 79%) formed the study cohort (Table 1). Median age at diagnosis was 6.5 years (range, 0.3 to 15 years). Risk group classification before 2001 derived from National Cancer Institute criteria, and then, subsequent to 2001, was based on previously published institutional criteria¹⁰⁾. Twenty patients (38%) were classified as low or standard risk ALL, and 33 (62%)

were classified as high or very high risk ALL. Of 41 patients with available cytogenetic studies at diagnosis, 8 had high risk features including 4 patients with *BCR-ABL1*, 3 with *E2A-PBX1*, and 1 patient with *MLL* gene rearrangement.

All patients in the study cohort were diagnosed with first bone marrow relapse at a median of 32.6 months since achieving CR (range 1.1 to 118) (Table 2). For the purposes of risk stratification according to duration of first CR, patients were categorized into early relapse (<12 months since CR, n=11, 21%), intermediate relapse (≥12 months and <36 months since CR, n=18, 34%), and late relapse groups (≥36 months since CR, n=24, 45%)⁷⁾.

2) Transplantation

All patients underwent allogeneic HSCT after having achieved second CR (Table 3). Median age at transplantation was 9.7 years (range, 0.9 to 20.7 years). Similar numbers of sibling donor and unrelated donor transplantations were included (26 sibling, 49%; 27 unrelated HSCTs, 51%), but with regards to cell source, a far greater number of bone marrow transplantations (BMT) were included than granulocyte-colony stimulating factor mobilized peripheral blood stem cell transplantations (PBSCT) (42 BMTs, 79%; 11 PBSCTs, 21%).

As the study covered HSCTs undertaken during a lengthy period in time, HLA typing for the study cohort was also done with varying

Table 1. Patient Characteristics at Initial Diagnosis (n=53)

Characteristic	Value
Median age (yr)	6.5 (0.3-15)
Gender	
Male	42 (79)
Female	11 (21)
Median WBC count (/mm ³)	11,500 (880-306,500)
Risk group	
Low or standard	20 (38)
High or very high	33 (62)

Values are presented as median (range) or number (%).

WBC, white blood cell

Table 2. Patient Characteristics at First Relapse (n=53)

Characteristic	Value
Age (yr)	9.2 (0.6-20.3)
WBC count (/mm ³)	5,080 (900-242,000)
Time from CR to relapse (mo)	32.6 (1.1-118)
Early (<12)	11 (21)
Intermediate (≥12, <36)	18 (34)
Late (≥36)	24 (45)

Values are presented as median (range) or number (%).

CR, complete remission; WBC, white blood cell.

methodologies. Different modes of HLA typing posed a problem concerning patient classification according to HLA compatibility. A strict definition of “HLA-match” as an 8 of 8 allele complete match of high resolution-typed HLA, as is done currently in our institution, would classify many patients who underwent HSCT with a serologically matched donor, previous to implementation of high resolution typing, as having received “HLA-mismatched” transplantations. In order to resolve this issue, all patients were categorized according to time-appropriate HLA methodology; that is, an “HLA-match” was defined as a complete match of HLA tested between donor and recipient at that point in time, be the method serologic or molecular.

All but 2 patients received a total body irradiation (TBI)-based conditioning regimen, with TBI-cytarabine-cyclophosphamide±anti-thymocyte globulin (ATG) being the most commonly utilized regimen (n=31, 59%), followed by TBI-cyclophosphamide (n=15, 28%). Regimens without TBI included 1 busulfan-based and 1 carmustine-

based conditioning each. Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine and mini dose methotrexate (MTX) for 49 patients (92%), with the remaining patients receiving a combination of cyclosporine and mycophenolate mofetil±MTX.

2. Study endpoints

Major study endpoints included engraftment, incidence of acute GvHD (grades II to IV) and chronic GvHD, disease-free survival (DFS) and overall survival (OS). Neutrophil engraftment was defined as the first of 3 consecutive days in which the absolute neutrophil count (ANC) was $>1,000/\text{mm}^3$, and platelet engraftment was defined as the first of 3 consecutive days in which the platelet count was $>50,000/\text{mm}^3$ with no platelet transfusions in the past seven days. Acute and chronic GvHD were classified according to previously established criteria^{11,12}. DFS was defined as the time from HSCT till relapse or death, whichever came first. OS was defined as time from HSCT till death from any cause. Relapse rate and rate of 1-year transplant-related mortality (TRM) were also evaluated.

3. Statistical analyses

Prognostic factors for DFS were evaluated using Cox proportional hazards regression model. The following variables were analyzed: age at initial diagnosis, age at transplant, patient gender, white blood cell (WBC) count at diagnosis, WBC count at relapse, initial risk group, duration of first CR, donor type, cell source, HLA compatibility, ABO compatibility, and conditioning regimen. Variables with a *P* value of <0.1 on univariate study were entered in a multivariate model using the backward stepwise selection method. Incidence of acute and chronic GvHD, relapse and TRM rates were calculated using a cumulative incidence function with consideration of competing risks. Variables studied for DFS were also evaluated for contributing to acute and chronic GvHD, relapse rate and TRM rate using Gray's test. Again, factors with a *P* value of <0.1 were analyzed in a multivariate manner using Fine and Gray's proportional hazards model. DFS and OS were calculated with the Kaplan-Meier method and comparisons done with the log rank test. *P* values <0.05 were considered statistically significant. Statistical work was done on SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) and R package, ver. 2.10.1 (available from: <http://cran.r-project.org>).

Results

1. Engraftment data

Median infused cell counts were as follows: TNC $2.6 \times 10^8/\text{kg}$ (range, 0.7 to $42.1 \times 10^8/\text{kg}$), MNC $1.2 \times 10^8/\text{kg}$ (range, 0.5 to $35.7 \times 10^8/\text{kg}$), CD34+ $5.3 \times 10^6/\text{kg}$ (range, 0.6 to $81.4 \times 10^6/\text{kg}$), CD3+

Table 3. Transplantation Characteristics (n=53)

Characteristic	Value
Age at transplant (yr)	9.7 (0.9-20.7)
Donor type	
Sibling	26 (49)
Unrelated	27 (51)
Cell source	
BM	42 (79)
PBSC	11 (21)
Donor age (yr)	20.5 (1-40)
HLA compatibility*	
Match	38 (72)
Mismatch	15 (28)
Donor-recipient gender	
Female-male	13 (25)
Others	40 (76)
ABO compatibility	
Match	26 (49)
Mismatch	27 (51)
Conditioning regimen	
TBI-Ara-Cy±ATG	31 (59)
Others	22 (42)
GvHD prophylaxis	
CS+MTX	49 (92)
Others	4 (8)

Values are presented as median (range) or number (%).

BM, bone marrow; PBSC, G-CSF-mobilized peripheral blood stem cells; HLA, human leukocyte antigen; TBI, total body irradiation; Ara, cytarabine; Cy, cyclophosphamide; ATG, anti-thymocyte globulin; GvHD, graft-versus-host disease; CS, cyclosporine; MTX, methotrexate.

*HLA match includes either low or high resolution HLA match.

$5.2 \times 10^7/\text{kg}$ (range, 0.5 to $518 \times 10^7/\text{kg}$). All patients showed neutrophil engraftment at a median of 15 days (range, 8 to 31 days), while only 38 patients (72%) showed full recovery of platelet count to greater than $50,000/\text{mm}^3$ at a median of 26 days (range, 10 to 178 days) post-transplantation.

2. Incidence of acute and chronic GvHD

Acute GvHD of grade II or above was diagnosed in 24 patients at a median of 15 days post-transplantation (range, 5 to 81) for a cumulative incidence of $45.3 \pm 6.9\%$. Eighteen patients (34%) were diagnosed with grade II acute GvHD, and 3 patients each (6%) were diagnosed with grades III and IV GvHD. All 3 patients with grade IV GvHD died. Important risk factors for acute GvHD included age at transplant ($P=0.090$), donor type ($P<0.001$), and HLA compatibility ($P=0.002$), with only HLA compatibility having a significant effect on multivariate study (hazard ratio [HR], 2.41; 95% confidence interval [CI], 1.14 to 5.08; $P=0.021$).

Chronic GvHD was diagnosed in 16 patients (mild 5, 9%; moderate 10, 19%; severe 1, 2%) for a cumulative incidence of $28.5 \pm 6.3\%$. Median time at chronic GvHD diagnosis was 5 months after transplantation (range, 2.7 to 17.2). No one factor had a significant impact on chronic GvHD incidence.

3. Analysis of DFS

The estimated 5-year DFS for the entire cohort was $45.2 \pm 6.8\%$. On analyzing for prognostic factors for DFS, age at diagnosis ($P=0.071$), donor type ($P=0.010$), and HLA compatibility (0.021) proved to be important variables (Table 4). However, on multivariate study, only donor type had prognostic significance (HR, 2.75; 95% CI, 1.28 to 5.93; $P=0.010$), with superior DFS in recipients from sibling donors compared to unrelated donors. Patients with a long duration of first CR before HSCT did not have a survival advantage compared with patients who relapsed early.

DFS curves were redrawn in order to evaluate for potential comparable outcomes of MSD and MUD HSCT (Fig. 1). Five-year estimated DFS for MSD HSCT, MUD HSCT, and mismatched unrelated donor (MMUD) HSCT were as follows: $68 \pm 9.3\%$, $38.5 \pm 13.5\%$, $14.3 \pm 9.4\%$ respectively. Log-rank comparison of MSD and MUD HSCT showed a value bordering on statistically significant difference ($P=0.051$), while a comparison of MSD HSCT and MMUD HSCT showed clear differences in DFS ($P=0.002$).

4. Relapse and TRM incidence

Overall, 15 patients relapsed resulting in an estimated 5-year rate of disease relapse of $28.9 \pm 6.4\%$. All patients showed bone marrow (BM) relapse except for 1 patient who was diagnosed with isolated

testicular relapse 9 months post-transplantation. Analysis was done to determine factors significant for relapse using the variables utilized for study of DFS. Initial WBC count at diagnosis had prognostic relevance bordering on significance, with patients presenting with an

Table 4. Univariate Study of Disease-free Survival Prognostic Factors

Variable	No. (Number)	Events	P value
Age at diagnosis			0.071
≥ 1 and < 10	40	20	
< 1 or ≥ 10	13	10	
Donor type			0.010
Sibling	26	10	
Unrelated	27	20	
HLA compatibility*			0.021
Match	38	17	
Mismatch	15	13	
Age at transplant			0.847
< 10	27	15	
≥ 10	26	15	
Gender			0.166
Male	42	26	
Female	11	4	
WBC count at diagnosis			0.563
$< 50,000$	41	22	
$\geq 50,000$	12	8	
WBC count at relapse†			0.707
$< 10,000$	34	19	
$\geq 10,000$	16	10	
Initial risk group			0.222
Low-standard	20	9	
High-very high	33	21	
Duration of first CR (mo)			
$< 12 / \geq 12$ and < 36	11/18	7/13	0.524
$< 12 / \geq 36$	11/24	7/10	0.207
Cell source			0.478
BM	42	23	
PBSC	11	7	
ABO compatibility			0.837
Match	26	14	
Mismatch	27	16	
Conditioning regimen			0.884
TBI-Ara-Cy \pm ATG	31	19	
Others	22	11	

HLA, human leukocyte antigen; WBC, white blood cell; CR, complete remission; BM, bone marrow; PBSC, G-CSF-mobilized peripheral blood stem cells; TBI, total body irradiation; Ara, cytarabine; Cy, cyclophosphamide; ATG, anti-thymocyte globulin.

*HLA match includes either low or high resolution HLA match. †WBC count at relapse was unavailable in 3 patients who were initially treated and showed first relapse at another institution, and who were subsequently transferred to our hospital for further treatment, including HSCT.




Fig. 1. Estimated 5-year disease-free survival curves by donor type considering human leukocyte antigen compatibility. MSD, matched sibling donor; MUD, matched unrelated donor (high or low resolution); MMUD, mismatched unrelated donor (high or low resolution).

initial WBC count $\geq 50,000/\text{mm}^3$ more likely to relapse than those with lower counts ($P=0.082$). However, no one variable had a definite significant impact on rate of relapse, as determined by univariate analysis. All patients with BM relapse, except 2 who were lost to follow-up within 1 year of relapse, died. The patient with isolated testicular relapse underwent localized radiotherapy and chemotherapy and has survived for 89 months post-HSCT at last follow-up.

Another 15 patients died during the initial year post-transplantation due to causes other than relapse for a 1-year cumulative TRM incidence of $26.4 \pm 6.1\%$. Although univariate study of prognostic factors for TRM revealed donor type ($P=0.002$) and HLA compatibility ($P=0.022$) to be significant variables, none proved to maintain significance on multivariate study. Causes of TRM were as follows: pneumonia and acute respiratory distress syndrome 5, acute GvHD 3, thrombotic microangiopathy 2, pulmonary hemorrhage 2, veno-occlusive disease 1, sepsis 1, and acute renal failure 1. Nearly all non-relapse deaths occurred during the first year post-transplantation, with only 1 patient dying of chronic GvHD beyond this period.

5. Analysis of overall survival

The estimated 5-year OS for the entire cohort was $48.3 \pm 7\%$, showing a rate similar to the DFS. Reanalysis according to donor type with consideration of HLA compatibility resulted in the following OS rates: $75 \pm 8.9\%$ for MSD, $38.5 \pm 13.5\%$ for MUD, and $14.3 \pm 9.4\%$ for MMUD. Significant differences were noted when comparing the OS for MSD to that for either MUD ($P=0.018$) or MMUD ($P<0.001$).

Discussion

In this study, we report the outcomes of allogeneic HSCT undertaken

in children with ALL in second CR at a single institution during a lengthy period spanning more than 17 years. As far as we know, this is the first such report to derive from a Korean pediatric population.

The overall $45.3 \pm 6.9\%$ incidence of grade II to IV acute GvHD was considerably higher than reported rates in similar studies^{6,7}. The lack of routine *in vivo* T cell depletion with the use of ATG in the conditioning regimen for unrelated HSCTs done in the early period of the study may have had a role in increasing acute GvHD incidence. Cumulative incidence of $28.5 \pm 6.3\%$ for chronic GvHD was similar to the 22 to 27% reported from large cohort studies comprising both matched sibling and alternative donor HSCTs^{13,14}.

Overall, less than half the patients of the cohort survived disease-free. Also of note, the DFS and OS were similar emphasizing once more the extremely poor prognosis once a patient relapsed after HSCT. Excluding patients lost to follow-up, only 1 patient with isolated testicular relapse survived after relapse. In comparison, the DFS of 45.2% for the overall cohort is similar to previous reports based on HSCTs from heterogeneous donor types^{7,15}, but is considerably lower than the 67.1% 3-year DFS reported by one study⁶ which also included patients transplanted in first CR. Sub-analysis according to donor type lends some evidence for this discrepancy; although the estimated DFS of 68% for MSD HSCT was superior or comparable to previous results, the 38.5% DFS for MUD HSCT was much lower^{6,7}. Hence, unlike these reports which conclude on similar results for MSD and alternative donor HSCT, there was at least a trend towards a significant difference when comparing MSD and MUD HSCT ($P=0.051$).

Akin to the survival analyses, the regression modeling revealed that donor type, sibling versus unrelated donor, was the only significant prognostic factor for DFS. As all sibling donors were fully HLA-matched except for 1 donor who showed 1 allele mismatch with a sibling patient, how much of the prognostic significance of a sibling donor pertains to HLA compatibility, and how much is based on the potential benefits of a sibling donor beyond standard HLA typing would require further comparative study of a cohort consisting of MSD and high resolution-typed MUD HSCTs only. Our study also revealed the lack of a survival benefit for patients who underwent HSCT after a lengthy period of first remission compared to those who relapsed early on during treatment. This is an important finding considering that nearly half the patients (45%) in our cohort relapsed after at least 3 years of CR status. Previous studies indicate either a survival advantage for late relapse patients⁷, or are inconclusive as to whether HSCT improves upon the approximately 50% survival rate based on chemotherapy only¹⁶, and our results underscore the important question of whether patients with late relapse may benefit from HSCT.

No one factor had a significant impact on the 29% cumulative relapse rate, although a previous study has shown that HSCT from an MUD leads to a lower rate of relapse¹⁷. With regards to 1-year TRM, both donor type and HLA compatibility were significant factors individually, but none proved to be important on multivariate study, possibly due to data multicollinearity between the 2 variables. However, it is important to note that donor type, which was the only significant factor for DFS, was also important in terms of 1-year TRM.

We draw attention to the limitations of our study. First, as mentioned previously, the lengthy span of time during which the HSCTs took place led to heterogeneity in HLA typing methods, from low to high resolution typing, posing problems for patient classification according to HLA compatibility. Decision as to whether a patient was matched or mismatched was, therefore, based on time-appropriate HLA methodology. Survival analyses with subclassification of MUD HSCT according to HLA typing method, for example high resolution HLA-MUD versus low resolution HLA-MUD, would have given some insight into the importance of typing accuracy. However, the number of patients in each subgroup then proved to be too few to allow for accurate analysis. Lack of specific cytogenetic data for each patient is also conspicuous and was due to many patients transplanted in the early period not having accurate cytogenetic characterization. Cytogenetic studies and minimal residual disease monitoring pre-transplant based on such studies have since gained importance¹⁸, and should be incorporated into future studies of more recent cohorts.

Also, the potential efficacy of HSCT, especially in the MSD setting as shown by our results, should be tempered by the substantial risk for late effects in children who undergo HSCT. The number of physical organs and functions that are susceptible to delayed complications of transplantation are considerable, with 1 recent report indicating a 78% incidence of late effects amongst HSCT treated childhood cancer survivors¹⁹.

In conclusion then, with less than half the overall cohort surviving disease free, donor type had a significant impact on survival, possibly due to increased TRM resulting from unrelated donors. Survival rates for MSD HSCTs were comparable to previous studies, but those of unrelated HSCTs tended to be lower. Recognizing that many of the patients in our study underwent HSCT more than a decade ago, and understanding the major improvements in supportive care and HLA typing methods that have taken place since then, similar studies with more recently treated cohorts should be undertaken to conclude upon possible improvements in unrelated donor HSCT results. With more than half of childhood ALL patients in second CR failing to be cured by HSCT, both means of optimizing HSCT treatment through recognition of new prognostic factors and research into other novel therapeutic options remain necessary.

References

1. Gaynon PS. Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining. *Curr Hematol Malig Rep* 2007; 2:193-201.
2. Barrett AJ, Horowitz MM, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. *N Engl J Med* 1994;331:1253-8.
3. Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN, et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. *J Clin Oncol* 1999;17:197-207.
4. Matsuzaki A, Nagatoshi Y, Inada H, Nakayama H, Yanai F, Ayukawa H, et al. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group. *Pediatr Blood Cancer* 2005;45:111-20.
5. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. *Leukemia* 2002;16:2228-37.
6. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, et al. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. *Biol Blood Marrow Transplant* 2008;14:1245-52.
7. Smith AR, Baker KS, Defor TE, Verneris MR, Wagner JE, Macmillan ML. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. *Biol Blood Marrow Transplant* 2009; 15:1086-93.
8. Eapen M, Raetz E, Zhang MJ, Muchlenbein C, Devidas M, Abshire T, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Blood* 2006;107:4961-7.
9. Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO, et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. *Br J Haematol* 2003;122:24-9.
10. Lee JW, Lee KH, Kwon YJ, Lee DH, Chung NG, Jeong DC, et al. The effects of shortened dexamethasone administration on remission rate and potential complications during remission induction treatment for pediatric acute lymphoblastic leukemia. *Korean J Pediatr* 2007;50:1217-24.
11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant* 1995;15:825-8.
12. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant* 2005;11: 945-56.
13. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C, et al. Chronic graft-versus-host disease in children: incidence, risk factors, and

- impact on outcome. *Blood* 2002;100:1192-200.
14. Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. *Bone Marrow Transplant* 2001;27:727-30.
 15. Muñoz A, Diaz-Heredia C, Diaz MA, Badell I, Verdeguer A, Martinez A, et al. Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon). *Pediatr Hematol Oncol* 2008;25:245-59.
 16. Borgmann A, Baumgarten E, Schmid H, Dopfer R, Ebell W, Göbel U, et al. Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative? *Bone Marrow Transplant* 1997;20:939-44.
 17. Gassas A, Sung L, Saunders EF, Doyle J. Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: significantly lower relapse rate in unrelated transplantations. *Bone Marrow Transplant* 2007;40:951-5.
 18. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2007;48:93-100.
 19. Ishida Y, Honda M, Ozono S, Okamura J, Asami K, Maeda N, et al. Late effects and quality of life of childhood cancer survivors: part 1. Impact of stem cell transplantation. *Int J Hematol* 2010;91:865-76.